



IPO INSIGHTS



Rainbow Children's Medicare Ltd

Issue Dates - Opens: 27-04-2022 | Closes: 29-04-2022

IPO Note	<ol style="list-style-type: none"> 1. Leading Multispeciality Healthcare service provider for Children's Medicare 2. Currently present in North and South India 3. Expensive Valuation
Rating	★★ (Average)

IPO SNAPSHOT

Issue Size	₹ 1580.85 Crores
Issue Type	Fresh Issue & Offer For Sale
Fresh Issue	₹ 280.00 Crores
Offer for Sale	₹ 1300.85 Crores
Face Value Per Share	₹ 10
Price Band Per Share	₹ 516- ₹ 542
Minimum Lot Size	27 shares
Listing On	BSE & NSE
Pre-Issue Promoter Shareholding	62.19%
Post-Issue Promoter Shareholding	49.83%

Registrar to the Issue

Kfin Technologies Limited

IPO SNAPSHOT – Rainbow Children’s Medicare Ltd

About the Company	<ul style="list-style-type: none"> ▪ Incorporated on August 7, 1998. ▪ Leading Multi-Speciality Paediatric and obstetrics & gynaecology hospital chain in India. ▪ Operates 14 Hospitals & 3 Clinics in 6 cities with a total bed capacity of 1500 beds as on September 30, 2021 ▪ Core Specialities: Paediatrics, Obstetrics, Gynaecology ▪ Highest number of hospital beds amongst comparable players in the maternity & paediatric healthcare delivery sector as of March 31, 2021 ▪ Had 641 full-time doctors & 1947 visiting doctors as on December 31, 2021. ▪ Follows a hub-and-spoke model in Hyderabad with Banjara Hills Hospital with 250 beds – being the hub & 4 spokes at 4 locations in Hyderabad namely Secunderabad, LB Nagar, Kondapur and Hydernagar ▪ 5 of the RCML hospitals are accredited by NABH ▪ 3 of the RCML hospitals are certified by EDGE ▪ Increased Scale of reach to patients through robust digital ecosystem. 																																				
Competitive Strengths	<ul style="list-style-type: none"> ▪ Ability to conceptualize, create & operate specialized children’s hospitals ▪ Leading paediatric, multi-speciality healthcare-chain with strong clinical expertise in managing complex diseases ▪ Comprehensive perinatal-care provider with synergies between paediatric, obstetrics and gynaecology services ▪ Hub and spoke model that provides synergies and ensures better care and access for patients ▪ Proven ability to attract, train and retain high-caliber medical professionals ▪ Strong track record of growth, operational and financial performance ▪ Experienced senior management team with strong institutional shareholder support 																																				
Financials (₹ in Millions)	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="background-color: #002060; color: white;">Particulars</th> <th style="background-color: #002060; color: white;">31-3-2019</th> <th style="background-color: #002060; color: white;">31-3-2020</th> <th style="background-color: #002060; color: white;">31-3-2021</th> <th style="background-color: #002060; color: white;">31-12-2021</th> <th style="background-color: #002060; color: white;">Y-o-Y</th> </tr> </thead> <tbody> <tr> <td>Revenue</td> <td>5427.92</td> <td>7193.91</td> <td>6500.47</td> <td>7613.11</td> <td style="color: red;">-10%</td> </tr> <tr> <td>EBITDA</td> <td>1568.66</td> <td>2073.73</td> <td>1730.97</td> <td>2694.93</td> <td style="color: red;">-17%</td> </tr> <tr> <td>EBITDA Margin</td> <td style="text-align: center;">28.9%</td> <td style="text-align: center;">28.8%</td> <td style="text-align: center;">26.6%</td> <td style="text-align: center;">35.4%</td> <td></td> </tr> <tr> <td>PAT</td> <td>445.90</td> <td>553.4</td> <td>395.68</td> <td>1264.13</td> <td style="color: red;">-29%</td> </tr> <tr> <td>PAT Margin</td> <td style="text-align: center;">8.2%</td> <td style="text-align: center;">7.7%</td> <td style="text-align: center;">6.1%</td> <td style="text-align: center;">16.6%</td> <td></td> </tr> </tbody> </table>	Particulars	31-3-2019	31-3-2020	31-3-2021	31-12-2021	Y-o-Y	Revenue	5427.92	7193.91	6500.47	7613.11	-10%	EBITDA	1568.66	2073.73	1730.97	2694.93	-17%	EBITDA Margin	28.9%	28.8%	26.6%	35.4%		PAT	445.90	553.4	395.68	1264.13	-29%	PAT Margin	8.2%	7.7%	6.1%	16.6%	
Particulars	31-3-2019	31-3-2020	31-3-2021	31-12-2021	Y-o-Y																																
Revenue	5427.92	7193.91	6500.47	7613.11	-10%																																
EBITDA	1568.66	2073.73	1730.97	2694.93	-17%																																
EBITDA Margin	28.9%	28.8%	26.6%	35.4%																																	
PAT	445.90	553.4	395.68	1264.13	-29%																																
PAT Margin	8.2%	7.7%	6.1%	16.6%																																	
Valuation	<ul style="list-style-type: none"> ▪ At FY21 EPS of 5.14, P/E is 105.40 at Upper Price Band 																																				
Peers	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="background-color: #002060; color: white;">Sr. No.</th> <th style="background-color: #002060; color: white;">Name</th> <th style="background-color: #002060; color: white;">TTM P/E</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">1</td> <td style="text-align: center;">Apollo Hospital Enterprises</td> <td style="text-align: center;">428.88</td> </tr> <tr> <td style="text-align: center;">2</td> <td style="text-align: center;">Fortis Healthcare</td> <td style="text-align: center;">NA</td> </tr> <tr> <td style="text-align: center;">3</td> <td style="text-align: center;">Narayana Hrudayalaya</td> <td style="text-align: center;">NA</td> </tr> <tr> <td style="text-align: center;">4</td> <td style="text-align: center;">Max Healthcare Institute</td> <td style="text-align: center;">NA</td> </tr> <tr> <td style="text-align: center;">5</td> <td style="text-align: center;">Krishna Institute of Medical Sciences</td> <td style="text-align: center;">54.19</td> </tr> </tbody> </table>	Sr. No.	Name	TTM P/E	1	Apollo Hospital Enterprises	428.88	2	Fortis Healthcare	NA	3	Narayana Hrudayalaya	NA	4	Max Healthcare Institute	NA	5	Krishna Institute of Medical Sciences	54.19																		
Sr. No.	Name	TTM P/E																																			
1	Apollo Hospital Enterprises	428.88																																			
2	Fortis Healthcare	NA																																			
3	Narayana Hrudayalaya	NA																																			
4	Max Healthcare Institute	NA																																			
5	Krishna Institute of Medical Sciences	54.19																																			
Promoters	<ul style="list-style-type: none"> ▪ Dr. Ramesh Kancharla, Dr. Dineshkumar Chirla & Dr. Adarsh Kancharla 																																				

DISCLAIMER
 The information provided by or in this newsletter is generally from the press reports, electronic media, research websites and other media. It also includes information from interviews conducted, analysis, views expressed by our research team. Investors should not rely solely on the information contained in this publication and must make their own investment decision based on their specific objectives and financial positions and using such independent advisor as they believe necessary. The material and the information provided herein are not and should not be construed as an advice to buy or sell any of the securities named in this newsletter. SIHL may or may not hold positions in any of the securities named in this newsletter as a part of its business. Past performance is not necessarily an indication of future performance. SIHL does not assure for accuracy and correctness of information of reports in this newsletter.

